SPRY
ARS Pharmaceuticals, Inc.NASDAQHealthcare$8.30+2.34%ClosedMarket Cap: $824.2M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
7.16
P/S
9.78
EV/EBITDA
-5.13
DCF Value
$-4.49
FCF Yield
-20.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.8%
Operating Margin
-212.9%
Net Margin
-203.3%
ROE
-100.3%
ROA
-54.7%
ROIC
-62.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $28.1M | $-41.3M | $-0.42 |
| FY 2025 | $84.3M | $-171.3M | $-1.74 |
| Q3 2025 | $32.5M | $-51.2M | $-0.52 |
| Q2 2025 | $15.7M | $-44.9M | $-0.46 |
Trading Activity
Insider Trades
View AllScott Kathleen D.officer: Chief Financial Officer
SellMon Jan 05
Karas Ericofficer: Chief Commercial Officer
SellMon Jan 05
Fitzpatrick Alexander Aofficer: Chief Legal Officer
SellMon Jan 05
Dorsey Brianofficer: Chief Operating Officer
SellMon Jan 05
Chakma Justinofficer: Chief Business Officer
SellMon Jan 05
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.93
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.